American Journal of Cardiology
Volume 103, Issue 3 , Pages 387-392, 1 February 2009

Effect of Combination Nicotinic Acid and Gemfibrozil Treatment on Intermediate Density Lipoprotein, and Subclasses of Low Density Lipoprotein and High Density Lipoprotein in Patients With Combined Hyperlipidemia

  • H. Robert Superko, MD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia
    • Cholesterol, Genetics, and Heart Disease Institute, Portola Valley, California
    • Corresponding Author InformationCorresponding author: Tel: 678-843-6052; fax: 678-843-6051
    • ,
  • Brenda C. Garrett, RN

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • ,
  • Spencer B. King III, MD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia
    • ,
  • Kathryn M. Momary, PharmD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia
    • ,
  • Nicolas A. Chronos, MD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • ,
  • Peter D. Wood, PhD, DSc

      Affiliations

    • Stanford University School of Medicine, Stanford, California

Received 30 May 2008; received in revised form 12 September 2008; accepted 12 September 2008. published online 28 November 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported by Parke-Davis Pharmaceuticals, Warner-Lambert Company, Morris Plains, New Jersey, and the Cholesterol, Genetics, and Heart Disease Institute, Portola Valley, California.

PII: S0002-9149(08)01712-8

doi:10.1016/j.amjcard.2008.09.103

American Journal of Cardiology
Volume 103, Issue 3 , Pages 387-392, 1 February 2009

Article Tools

* Image Usage & Resolution